Table 1.
Baseline characteristics of patients included in the APT trial, and in the current analysis
| Characteristics | Total study population | Subpopulation with any assay | Subpopulation with all assays |
|---|---|---|---|
| Patients | N = 406 | N = 328 | N = 147 |
| Age | |||
| Mean (SD) | 55.2 (10.5) | 56.0 (10.7) | 55.6 (10.6) |
| Race | |||
| White | 351 (86%) | 279 (85%) | 130 (88%) |
| Black or AA | 28 (7%) | 27 (8%) | 7 (5%) |
| Asian | 11 (3%) | 10 (3%) | 5 (3%) |
| Other | 16 (4%) | 12 (3%) | 5 (3%) |
| Primary size (cm) | |||
| Mean (SD) | 1.17 (0.64) | 1.22 (0.64) | 1.26 (0.55) |
| Histologic grade | |||
| 1 | 44 (11%) | 30 (9%) | 15 (10%) |
| 2 | 131 (32%) | 109 (33%) | 49 (33%) |
| 3 | 228 (56%) | 189 (58%) | 83 (56%) |
| Missing | 3 (1%) | 0 | 0 |
| ER status | |||
| Positive | 265 (65%) | 219 (67%) | 100 (68%) |
| Negative | 141 (35%) | 109 (33%) | 47 (32%) |
| PR status | |||
| Positive | 209 (51%) | 176 (54%) | 81 (55%) |
| Negative | 197 (49%) | 152 (46%) | 66 (45%) |
| HR status | |||
| Positive | 272 (67%) | 226 (69%) | 102 (69%) |
| Negative | 134 (33%) | 102 (31%) | 45 (31%) |
| Molecular subtype | |||
| Basal-like | n.a. | 21 (8%) | 9 (6%) |
| Her2-enriched | n.a. | 176 (65%) | 98 (67%) |
| Luminal A | n.a. | 35 (13%) | 18 (12%) |
| Luminal B | n.a. | 38 (14%) | 22 (15%) |
AA, African American; ER, estrogen receptor; HR, hormonal receptor; PR, progesterone receptor.